Shannonside Region: State Invests Nearly €2.63 Million on Ozempic

New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.

New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year.

Longford and Westmeath had the highest expenses, totaling about €1.4 million.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Roscommon recorded spending of just under €548,000, while Sligo and Leitrim recorded just over €685,000. Nationally, the total expenditure is close to €40 million.

These figures encompass prescriptions for patients receiving general medical services and those with long-term illnesses. Health tracking apps like Shotlee can help monitor medication adherence.

Source Information

Originally published by Shannonside.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read

Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read

Health Technology & Access

GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight

The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.

6 min read

Same topic: Healthcare

All Healthcare articles →

Finance

Should You Invest in Novo Nordisk, the Ozempic Manufacturer, in 2026?

Investing in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, has faced challenges recently, with shares declining. However, recent FDA approval of an oral form of Wegovy could change the company's trajectory. Analyzing competition and market dynamics is vital for investment decisions.

2 min read

Finance

Semaglutide to Potentially Boost Ajanta Pharma's Growth Trajectory | Stock Market Update

Ajanta Pharma's recent agreement to market semaglutide across emerging markets has the potential to influence its medium-term growth. The company's established presence and strategic focus on branded generics contribute to a positive outlook. Financial analysts predict substantial revenue increases in the coming years.

3 min read

Health

Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic

Uzbekistan has registered Semavik, a Russian-produced medication containing semaglutide, designed to treat type 2 diabetes and obesity. This marks the first local equivalent of the Danish drug Ozempic in the country. The approval addresses the increasing prevalence of metabolic diseases.

1 min read

More in Health

Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.

7 min read

Health & Wellness

Ozempic and the Shift: Real Data on America's Obesity Rates

New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.

7 min read

Health & Wellness

Beyond the Headlines: Navigating Severe GLP-1 Side Effects

Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.

7 min read